Key terms
About ALLK
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALLK news
Apr 24
12:25am ET
Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments
Apr 23
5:22pm ET
Allakos Inc. Announces Board of Directors Reshuffle
Mar 19
1:38am ET
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Mar 14
6:35pm ET
TD Cowen Remains a Hold on Allakos (ALLK)
Mar 14
4:07pm ET
Allakos says restructuring extends cash runway into mid-2026
Mar 14
4:05pm ET
Allakos reports Q4 EPS (71c), consensus (47c)
Feb 26
4:10pm ET
Analysts’ Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)
Feb 26
7:30am ET
Allakos presents preclinical data on AK006 at AAAAI meeting
Feb 12
8:19am ET
Allakos Inc Reveals Breakthrough AK006 Data in Allergy Journal
Feb 12
7:13am ET
Allakos announces publication on AK006 mast cell inhibition
No recent press releases are available for ALLK
ALLK Financials
Key terms
Ad Feedback
ALLK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALLK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range